Exhibit 99.1 HUTCHMED Reports 2022 Interim Results and Provides Business Updates Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA ® and ORPATHYS® growth First presentation of SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L+ post-TAGRISSO® NSCLC1 patients with high MET 2levels and no prior chemotherapy Initiated six new trials thus far in 2022 with a further six starting, including with five new drug candidates FRESCO-2 Phase III, our first glob ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2021 Earnings Conference Call March 3, 2022 8:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chief Scientific Officer Marek Kania - Executive Vice President, Managing Director and Chief Medical Officer, International Mark Lee - Senior Vice President, Corporate Finance & Development Johnny Cheng - Executive Director and Chief Financial Offic ...

Exhibit 99.1 HUTCHMED Reports 2021 Full Year Results and Provides Business Updates Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE growth and the 2021 launches of SULANDA and ORPATHYS; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS in lung cancer, kidney and gastric cancer during 2021; Broad late-stage development program – currently enrolling 13 registration studies on 6 assets – with enrollment on the 691 patient FRESCO-2 global Phase ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark one) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 co ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR Date of event requiring this shell comp ...

HUTCHMED (China) Limited (NASDAQ:HCM) Q2 2021 Earnings Conference Call July 28, 2021 8:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Mark Lee - Senior Vice President Corporate Finance & Development Wei-Guo Su - Chief Scientific Officer Marek Kania - Managing Director for HUTCHMED International & Chief Medical Officer Conference Call Participants Alec Stranahan - Bank of America Louise Chen - Cantor David Ng - Macquarie Paul Choi - Goldman Sachs Mike Mitchell - Panmure Gordon Operato ...

Hutchison China MediTech Limited (NASDAQ:HCM) Q4 2020 Earnings Conference Call March 4, 2021 8:00 AM ET Company Participants Christian Hogg - CEO Wei-guo Su - CSO & Head, R&D Marek Kania - CMO Johnny Cheng - CFO Conference Call Participants Louise Chen - Cantor Ethan Ding - Morgan Stanley Alec Stranahan - Bank of America Paul Choi - Goldman Sachs John Newman - Canaccord Genuity Tony Ren - CLSA Rajan Sharma - Deutsche Bank Christian Hogg Okay. Thank you. This is Christian Hogg, CEO of HUTCHMED. And today we ...